Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Integra Lifesciences Holdings (IART) Total Non-Current Liabilities (2016 - 2025)

Historic Total Non-Current Liabilities for Integra Lifesciences Holdings (IART) over the last 17 years, with Q3 2025 value amounting to $2.4 billion.

  • Integra Lifesciences Holdings' Total Non-Current Liabilities rose 90.11% to $2.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.4 billion, marking a year-over-year increase of 90.11%. This contributed to the annual value of $2.3 billion for FY2024, which is 1763.86% up from last year.
  • Latest data reveals that Integra Lifesciences Holdings reported Total Non-Current Liabilities of $2.4 billion as of Q3 2025, which was up 90.11% from $2.4 billion recorded in Q2 2025.
  • In the past 5 years, Integra Lifesciences Holdings' Total Non-Current Liabilities ranged from a high of $2.4 billion in Q2 2024 and a low of $1.9 billion during Q1 2023
  • Its 5-year average for Total Non-Current Liabilities is $2.1 billion, with a median of $2.0 billion in 2023.
  • In the last 5 years, Integra Lifesciences Holdings' Total Non-Current Liabilities crashed by 465.71% in 2022 and then soared by 2289.31% in 2024.
  • Integra Lifesciences Holdings' Total Non-Current Liabilities (Quarter) stood at $2.0 billion in 2021, then fell by 1.54% to $1.9 billion in 2022, then increased by 2.43% to $2.0 billion in 2023, then increased by 17.64% to $2.3 billion in 2024, then grew by 1.27% to $2.4 billion in 2025.
  • Its Total Non-Current Liabilities stands at $2.4 billion for Q3 2025, versus $2.4 billion for Q2 2025 and $2.4 billion for Q1 2025.